CD4 and Cowden disease: In the present study, we utilize this novel CRA for rare gluten-specific CD4+ T cells with the aim of optimizing blood collection and processing to monitor the effects of an experimental peptide immunotherapy (Nexvax2) for CD during a phase 2 clinical trial.